Research

Hormonal

Roux-en-Y gastric bypass (RYGB) induces type 2 diabetes remission primarily by restoring beta-cell glucose sensitivity, whereas improvements in insulin sensitivity are proportional to weight loss and do not independently predict remission.

For patients undergoing gastric bypass, weight loss alone does not guarantee diabetes remission. The key biological factor is the recovery of the pancreas's ability to sense and respond to glucose (beta-cell sensitivity). Patients with severe initial beta-cell dysfunction may not achieve remission even with significant weight loss. Monitoring metabolic markers beyond weight is crucial.

GoodQualifiesHIGH confidence
In morbid obesity, Roux-en-Y gastric bypass causes rapid and profound metabolic adaptations; insulin sensitivity improves in proportion to the weight loss, and beta-cell glucose sensitivity increases independently of weight loss. Over a period of 1 yr after surgery, diabetes remission depends on the starting degree of beta-cell dysfunction.
Monica Nannipieri et al. · The Journal of Clinical Endocrinology & Metabolism · 2011

Why this rating

Prospective clinical study with rigorous metabolic testing (OGTT modeling) and clear statistical predictors, though limited to a single center and specific surgical technique.

Source

The Role of β-Cell Function and Insulin Sensitivity in the Remission of Type 2 Diabetes after Gastric Bypass Surgery

Monica Nannipieri et al. · The Journal of Clinical Endocrinology & Metabolism · 2011

DOI 10.1210/jc.2011-0446

cohort · n=43Cited 180×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →